替莫唑胺与尼莫司汀在脑恶性胶质瘤化疗中的疗效对比研究  

Comparison of the clinical effect between temozolomide and nimustine in the treatment of malignant gliomas

作　　者：王耀伍[1] 尹春丽[1] 张宏义[1] 杨郁野[1] 廖珩[1] 张坤[1] 崔守章 

机构地区：[1]唐山市工人医院,河北唐山063000 [2]唐山新区第二医院,河北唐山063000

出　　处：《中国医院药学杂志》2011年第16期1360-1362,共3页Chinese Journal of Hospital Pharmacy

基　　金：卫生部指定项目(编号:w200601004)

摘　　要：目的:观察对比替莫唑胺与尼莫司汀在恶性胶质瘤(WHOⅢ,Ⅳ)的疗效。方法:120例恶性胶质瘤患者随机分为替莫唑胺治疗组及尼莫司汀对照组,治疗至少4个疗程,观察有效率、无进展生存时间、总生存时间及不良反应。结果:替莫唑胺较尼莫司汀有更高的有效率,生存时间长,不良反应较小。结论:替莫唑胺治疗恶性胶质瘤比尼莫司汀更有优势。OBJECTIVE To assess and compare the clinical effects of temozolomide and nimustine in the treatment of malignant gliomas（WHO III,IV）.METHODS 120 malignant gliomas cases were divided into temozolomide group and nimustine group randomly,with at least 4 periods of treatment.The effective ratio,progression-free survival time,overall survival time and adverse reactions were observed.RESULTS Comparing with nimustine,the temozolomide has better clinical effect,longer survival time and less adverse reactions.CONCLUSION Temozolomide is better than nimustine in the treatment of malignant gliomas.

关 键 词：替莫唑胺 尼莫司汀 恶性胶质瘤 

分 类 号：R969[医药卫生—药理学]